中位无进展生存期为6个月。
在两项研究中，主要功效评估指标是无进展生存期。
In both studies, the primary efficacy endpoint was progression-free survival.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
首要观察终点从总生存期(OS)改为无进展生存期(PFS)。
The primary end point was amended from overall survival (OS) to progression-free survival (PFS).
主要指标是总生存期，次要指标包括无进展生存期(PFS)和客观反应率(ORR)。
The primary endpoint was overall survival, and secondary endpoints included PFS and objective response rate (ORR).
术后替莫唑胺化疗组中位无进展生存期较单纯手术组显著延长（P<0.05），其余各组之间差异无统计学意义。
PFS of temozolomide chemotherapy group is higher than that of single operation group(P<0.05), and there were no significant differences of PFS between the other groups.
即使无进展生存期的中位数看起来不相同，风险比是0.6。“因为存在一个重要的患者子集通过一个重要途径受益。”
Even though the median in PFS doesn't look different, the HR is 0.6 "because there is a significant patient subset who benefit in a significant way. ""
他指出，研究结果还表明，患者的一个子集可能表现出更显著的效应。这在无进展生存期（PFS）的结果中能明显地看出来。
The findings also suggest that a subset of patients may be achieving a more significant benefit. This is apparent in the results of PFS, he pointed out.
目的：前列腺癌内分泌治疗后发现进展速度存在较大差异，为了改善其预后，本文探讨前列腺癌内分泌治疗后无进展生存期的影响因素。
This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
研究人员提到，在两组中总生存期和无进展生存也没有差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
研究人员提到，在两组中总生存期和无进展生存也没有差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
应用推荐